The damaging impact of tariffs on intellectual property

April 30, 2025

This article was originally published in IAM on April 24th, 2025

By Kirti Gupta

Economic statecraft has reached new levels with the United States levying the steepest increase in tariffs on foreign goods in the last 150 years. While the focus of these tariffs in popular media is consumer goods, we all live in the knowledge economy.

A few decades ago, 80% of the market value of S&P 500 firms was explained by their labour and capital assets. Today, that has reversed: 80% of their market value is explained by intangible assets – ideas, know-how, and intellectual property (IP).

What is the impact of the impact of these tariffs on IP? Some economists have been analyzing this question lately. The brief answer is that IP licensing revenues of US companies are likely to decrease, and IP enforcement abroad is likely to weaken, unless specific action is taken to counteract these effects proactively.

Read the full article in IAM.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor